AU2020240017A1 - Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof - Google Patents

Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof Download PDF

Info

Publication number
AU2020240017A1
AU2020240017A1 AU2020240017A AU2020240017A AU2020240017A1 AU 2020240017 A1 AU2020240017 A1 AU 2020240017A1 AU 2020240017 A AU2020240017 A AU 2020240017A AU 2020240017 A AU2020240017 A AU 2020240017A AU 2020240017 A1 AU2020240017 A1 AU 2020240017A1
Authority
AU
Australia
Prior art keywords
abiraterone
pharmaceutical formulation
patient
crystalline
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020240017A
Other languages
English (en)
Inventor
Urvi GALA
Dave Miller
Angela SPANGENBERG
Robert O. Williams Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Austinpx LLC
Original Assignee
University of Texas System
University of Texas at Austin
Austinpx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, Austinpx LLC filed Critical University of Texas System
Publication of AU2020240017A1 publication Critical patent/AU2020240017A1/en
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, AustinPx, LLC reassignment BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Amend patent request/document other than specification (104) Assignors: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLC
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020240017A 2019-03-18 2020-03-17 Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof Abandoned AU2020240017A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962820076P 2019-03-18 2019-03-18
US62/820,076 2019-03-18
US201962942111P 2019-11-30 2019-11-30
US62/942,111 2019-11-30
PCT/US2020/023066 WO2020190900A1 (en) 2019-03-18 2020-03-17 Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof

Publications (1)

Publication Number Publication Date
AU2020240017A1 true AU2020240017A1 (en) 2021-11-04

Family

ID=72521270

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020240017A Abandoned AU2020240017A1 (en) 2019-03-18 2020-03-17 Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof

Country Status (9)

Country Link
US (1) US20220362264A1 (https=)
EP (1) EP3941478A4 (https=)
JP (1) JP2022525425A (https=)
CN (1) CN113825514A (https=)
AU (1) AU2020240017A1 (https=)
BR (1) BR112021018540A2 (https=)
CA (1) CA3133620A1 (https=)
IL (1) IL286416A (https=)
WO (1) WO2020190900A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738369B1 (ko) * 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
EP3247334A1 (en) * 2015-01-20 2017-11-29 Merck Patent GmbH Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
WO2017037647A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical compositions of abiraterone
TWI717629B (zh) * 2017-08-28 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 Cyp17抑制劑的藥物組合物及其製備方法
WO2019060525A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF

Also Published As

Publication number Publication date
US20220362264A1 (en) 2022-11-17
BR112021018540A2 (pt) 2021-11-30
WO2020190900A1 (en) 2020-09-24
EP3941478A1 (en) 2022-01-26
JP2022525425A (ja) 2022-05-13
IL286416A (en) 2021-10-31
EP3941478A4 (en) 2022-12-28
WO2020190900A8 (en) 2021-10-14
CN113825514A (zh) 2021-12-21
CA3133620A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
AU2024202528B2 (en) Improved formulations of deferasirox and methods of making the same
US20190091339A1 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
Kalia et al. Solid dispersions: an approach towards enhancing dissolution rate
Kumar et al. Guargum and Eudragit® coated curcumin liquid solid tablets for colon specific drug delivery
JP6697473B2 (ja) 酢酸アビラテロンの複合体、その製造のための方法、およびそれらを含有する医薬組成物
TWI285116B (en) Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP2010525082A (ja) 固体投与形
EA027786B1 (ru) Пероральные лекарственные формы бендамустина и их терапевтическое применение
CN106265580A (zh) Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂
US20220401579A1 (en) Inclusion complexes of pharmaceuticals and cyclic oligomers
US20220185795A1 (en) Compound form having enhanced bioavailability and formulations thereof
US20220362264A1 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
TWI894266B (zh) 醋酸阿比特龍和尼拉帕尼之藥物配製物
Choudhari et al. Engineering Amorphous Solid Dispersions of Abiraterone Acetate via HPMC HME: A Polymer-Centric Hot-Melt Extrusion Strategy for Formulation-Driven Bioavailability Improvement.
EA046804B1 (ru) Форма соединения, обладающая повышенной биодоступностью, и ее составы

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Free format text: FORMER NAME(S): DISPERSOL TECHNOLOGIES, LLC ; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Owner name: AUSTINPX, LLC

Free format text: FORMER NAME(S): DISPERSOL TECHNOLOGIES, LLC ; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period